Rock Creek Group LP Takes Position in Cellebrite DI Ltd. $CLBT

Rock Creek Group LP acquired a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $2,704,000. Cellebrite DI comprises about 0.3% of Rock Creek Group LP’s holdings, making the stock its 27th biggest holding. Rock Creek Group LP owned approximately 0.06% of Cellebrite DI as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Advisory Services Network LLC acquired a new stake in Cellebrite DI during the 3rd quarter valued at $40,000. CWM LLC lifted its holdings in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. First Horizon Corp lifted its holdings in Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after purchasing an additional 2,337 shares during the last quarter. Vestcor Inc acquired a new stake in Cellebrite DI during the 3rd quarter valued at $70,000. Finally, PNC Financial Services Group Inc. lifted its holdings in Cellebrite DI by 114.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock valued at $83,000 after purchasing an additional 2,403 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Price Performance

CLBT stock opened at $14.73 on Friday. The stock has a market capitalization of $3.67 billion, a price-to-earnings ratio of 52.61, a PEG ratio of 1.58 and a beta of 1.15. The business’s fifty day moving average price is $13.27 and its two-hundred day moving average price is $15.29. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98.

Analyst Ratings Changes

Several brokerages have issued reports on CLBT. DA Davidson began coverage on Cellebrite DI in a report on Wednesday. They set a “buy” rating and a $20.00 price target for the company. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Needham & Company LLC cut their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 13,269 shares of company stock worth $169,592. 5.70% of the stock is owned by company insiders.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.